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Background: BRCA1 (breast cancer 1, early onset) missense mutations have been detected in familial breast and
ovarian cancers, but the role of these variants in cancer predisposition is often difficult to ascertain. In this work,
the molecular mechanisms affected in human cells by two BRCA1 missense variants, M1775R and A1789T,
both located in the second BRCT (BRCA1 C Terminus) domain, have been investigated. Both these variants
were isolated from familial breast cancer patients and the study of their effect on yeast cell transcriptome has
previously provided interesting clues to their possible role in the pathogenesis of breast cancer.
Methods: We compared by Human Whole Genome Microarrays the expression profiles of HeLa cells transfected
with one or the other variant and HeLa cells transfected with BRCA1 wild-type. Microarray data analysis was
performed by three comparisons: M1775R versus wild-type (M1775RvsWT-contrast), A1789T versus wild-type
(A1789TvsWT-contrast) and the mutated BRCT domain versus wild-type (MutvsWT-contrast), considering the two
variants as a single mutation of BRCT domain.
Results: 201 differentially expressed genes were found in M1775RvsWT-contrast, 313 in A1789TvsWT-contrast and
173 in MutvsWT-contrast. Most of these genes mapped in pathways deregulated in cancer, such as cell cycle
progression and DNA damage response and repair.
Conclusions: Our results represent the first molecular evidence of the pathogenetic role of M1775R, already
proposed by functional studies, and give support to a similar role for A1789T that we first hypothesized based on
the yeast cell experiments. This is in line with the very recently suggested role of BRCT domain as the main effector
of BRCA1 tumor suppressor activity.
Keywords: Gene expression, Microarray analysis, Missense mutations, BRCA1 gene, DNA damage, DNA repair,
Genomic instability, Cell proliferation, Breast neoplasms, ApoptosisBackground
BRCA1 is a tumor suppressor gene whose mutations
lead to breast and/or ovarian cancer. Human BRCA1
encodes a full-length protein of 1863 amino acids that is
an important player in controlling cell cycle progression.
It is involved in DNA damage response signaling net-
work, participating in G1/S, S and G2/M checkpoints.
BRCA1 is required for TP53 phosphorylation mediated
by ATM/ATR (ataxia telangiectasia mutated and ataxia
telangiectasia and Rad3 related) in response to DNA* Correspondence: silvia.pellegrini@med.unipi.it
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reproduction in any medium, provided the ordamage by ionizing or ultraviolet irradiation [1]. BRCA1
is also required for the TP53-mediated activation of
CDKN1A (cyclin-dependent kinase inhibitor 1A) tran-
scription that leads to cell cycle arrest [2]. Both BRCA1-
ATM and BRCA1-ATR interactions produce the phos-
phorylation of BRCA1 on specific Ser/Thr residues,
required for cell cycle arrest in S and G2 [3]. BRCA1 is
also involved in maintaining the cell genomic integrity.
It forms a complex with RBBP8 (retinoblastoma bind-
ing protein 8) and MRN (MRE11A/RAD50/NBN: mei-
otic recombination 11 homolog A (S. cerevisiae), RAD50
homolog (S. cerevisiae), nibrin) that partecipates in DNA
double-strand break repair mediated by homologous
recombination [4]. BRCA1 is furthermore able to act asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(BRCA1 associated RING domain 1) [5]. The most
recent hypothesis on BRCA1 concerns a role in main-
taining global heterochromatin integrity that might jus-
tify its tumor suppressor function [6].
BRCA1 consists of different functional domains: a N-
terminal RING finger domain, two nuclear localization
signals, a “SQ” cluster, a branched DNA-binding domain
and a C-terminal domain containing two BRCT (BRCA1
C Terminus) repeats [7]. BRCT repeats have been found
in many other proteins that regulate DNA damage
response and have a crucial role for their function [8].
BRCT repeats have been also described as phosphopeptide-
interacting motifs, facilitating the assembly of DNA
damage signaling complexes following checkpoint kinases
activation [9]. BRCT domains are also involved in the
transcriptional activity of BRCA1 and the second BRCT
repeat (aa 1760–1863) is critical for the activation of the
CDKN1A promoter [2]. Finally, a recent paper reported
that BRCA1 tumor suppression depends on BRCT
phosphoprotein binding [10].
Due to the relevance of this region for BRCA1 func-
tion, the study of mutations located in the BRCT
domain appears of particular interest.
Aim of this work was to investigate the effects on
human cell transcriptome of two missense variants,
M1775R and A1789T, both located within the second
BRCA1 BRCT domain and isolated from familial breast
cancers. In a previous work we examined the expression
profiles induced by these two mutations in yeast cells
[11]. In a recent paper from Guidugli et al. [12] these two
variants were tested in a homologous recombination and
a non-homologous end-joining assay in Hela cells. The
A1789T variant significantly altered the non-homologous
end-joining activity as compared to BRCA1 wild-type.
Here, we compared the expression profiles of HeLa
cells transfected with one or the other BRCA1 variant
with that of HeLa cells transfected with BRCA1 wild-
type. We found alterations of molecular mechanisms
critical for cell proliferation control and genome integ-




Both BRCA1 variants are located within the second
BRCT domain and, while M1775R has been widely
described as deleterious [13], A1789T has been studied
only by our group. In yeast cells both these mutations
reverted the growth suppression (small colony) pheno-
type, but only M1775R induced homologous recombin-
ation [14]. In HeLa cells A1789T significantly altered the
non-homologous end-joining activity as compared to
BRCA1 wild-type [12].HeLa cells transfection
Five aliquots of the same clone of HeLa G1 cells
were transiently transfected with the pcDNA3-BRCA1
wild-type (wt) vector, five with the pcDNA3-BRCA1-
M1775R derivative vector and five with the pcDNA3-
BRCA1-A1789T derivative vector as described by Guidugli
et al. [12].
Twenty-four hours after transfection, cells were
washed twice in PBS 1X, pelleted and immediately used
to extract RNA or proteins. The increased expression
of BRCA1 was assessed by Western Blot as showed by
Guidugli et al. [12].
Microarray
Gene expression was investigated by Whole Human
Genome Oligo Microarrays G4112F (Agilent Technolo-
gies, Palo Alto, CA, USA). A reference design was adopted
using as reference a pool of all the RNA samples from
wild-type clones.
Total RNA was extracted and DNase purified with
PerfectPure RNA Cultured Cell Kit (5 PRIME) (Eppendorf,
Hamburg, Germany). All RNAs, measured by NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies,
Inc. Wilmington, Del, USA), displayed a 260/280 OD ratio
> 1.9. The RNA integrity was verified by 1.2% agarose-
formaldehyde gel electrophoresis.
Total RNA samples were amplified and labelled with
Quick-Amp Labeling kit (Agilent Technologies, Palo
Alto, CA, USA). One hundred μl of In Situ Hybridisa-
tion Kit Plus mix (Agilent Technologies, Palo Alto, CA,
USA) containing 825 ng of Cy3-labelled aRNA (ranging
from 11 to 14 Cy3 pmoles) and 825 ng of Cy5-labelled
aRNA (18 Cy5 pmoles) were hybridized to each array
at 65 °C for 17 h under constant rotation. The arrays
were then washed 1 min at RT in 6X SSPE, 0.005%
TritonX-102; 1 min at 37 °C in 0.06X SSPE, 0.005%
Triton X-102; 30 sec at RT in Acetonitrile solution
(Agilent Technologies, Palo Alto, CA, USA) and 30 sec
at RT in Stabilization and Drying solution (Agilent Tech-
nologies, Palo Alto, CA, USA).
Microarray images were acquired by the Agilent scan-
ner G2565BA and intensity raw data were extracted by
the software Feature Extraction V10.5 (Agilent Tech-
nologies, Palo Alto, CA, USA). Data preprocessing and
statistical analysis were performed by LIMMA (LInear
Model of Microarray Analysis) [15] tool. The intensity
raw data were background-subtracted and normalized
within-arrays and between-arrays.
The contrast matrix was set to evaluate three com-
parisons: M1775RvsWT, A1789TvsWT and MutvsWT,
considering the two variants as a whole in the latter
case. Statistical significance to each gene in each com-
parison was assigned by B-statistic [16] and only genes
with B-statistic> 0 were included.
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[17,18]. The identification of the Gene Ontology terms
that are significantly over- or under-expressed in the lists
of differentially expressed genes (DEGs) was performed
with Onto-Express using an hypergeometric statistical
model [19,20]. The network of biological interactions
among DEGs and relevant biological terms was observed
by Coremine [21].
RT-qPCR
RT-qPCR was performed by the iCycler iQ instrument
(Biorad, Hercules, CA, USA) and the iQ SYBR Green
Supermix (Biorad, Hercules, CA, USA). Total RNAs
were reverse transcribed by QuantiTect Reverse Tran-
scription kit (Qiagen, Valencia, CA, USA). PCR primers
(listed in Table 1) were designed by Beacon Designer 4.0
(Premier Biosoft International, Palo Alto, CA, USA). RT-Table 1 Primer sequences
Gene Symbol Gene Name
Housekeeping genes
ACTB actin, beta
HPRT1 hypoxanthine phosphoribosyltransferase 1
GAPDH glyceraldehyde-3-phosphate dehydrogenase
TBP TATA box binding protein
Target genes
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip
EDN1 endothelin 1
EEF1E1 eukaryotic translation elongation factor 1 epsi
GPR56 G protein-coupled receptor 56
MRE11A MRE11 meiotic recombination 11 homolog A
NFKB1 nuclear factor of kappa light polypeptide gen
OBFC2B oligonucleotide/oligosaccharide-binding fold
PML promyelocytic leukemia
SOD2 superoxide dismutase 2, mitochondrialqPCR experiments were performed according to MIQE
guidelines [22].
Four housekeeping genes (see Table 1), tested for sta-
bility by geNorm [23], were used to normalize the dif-
ferential expression of target genes. The analysis was
performed considering the variants separately for the
M1775RvsWT- and the A1789TvsWT- contrasts, but
as a whole for the MutvsWT-contrast. One-tailed Wil-
coxon signed rank test was applied to evaluate the statis-
tical significance of results adopting a threshold of 0.05.
Western blot
Western Blot was performed as previously reported [12].
The level of protein expression was analyzed for:
GPR56 (anti-GPR56 rabbit polyclonal antibody H-93: sc-
99089, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,

















(S. cerevisiae) F: 5'-GATGATGAAGTCCGTGAGGCTATG-3'
R: 5'-TGTTGGTTGCTGCTGAGATGC-3'
e enhancer in B-cells 1 F: 5'-CCGTTGGGAATGGTGAGGTC-3'
R: 5'-TTGAGAATGAAGGTGGATGATTGC-3'






Figure 2 Venn diagram showing the numbers of pathways
shared by the three comparisons.
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nology, Inc., Santa Cruz, CA, USA, dilution 1:500);
NFKB1 (anti-NFKB1 mouse monoclonal antibody E-10:
sc-8414, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA, dilution 1:100) and PML (anti-PML mouse
monoclonal IgG2b clone 36.1-104, Upstate Biotechnol-
ogy, Inc., Waltham, MA, USA, dilution 1: 500).
Results
Microarray results
MutvsWT-contrast showed 173 DEGs (Additional file
1), M1775RvsWT-contrast 201 DEGs (Additional file 2)
and A1789TvsWT-contrast 313 DEGs (Additional file 3).
Twenty-four of these genes were differentially expressed
with similar fold changes in all the three comparisons
(Figure 1) (Additional file 4).
Complete information about the microarray experi-
ments and results can be retrieved from the ArrayEx-
press database at the European Bioinformatics Institute
[24] by the following accession number: E-MTAB-761.
Pathway analysis mapped 27 DEGs in 37 KEGG path-
ways for MutvsWT (Additional file 1), 40 DEGs in 58
KEGG pathways for M1775RvsWT (Additional file 2)
and 52 DEGs in 62 KEGG pathways for A1789TvsWT
(Additional file 3). In all the three comparisons many
pathways with high impact factor were involved in cancer.
Twenty-eight pathways were in common among the
three comparisons as indicated in Figure 2 (Additional
file 5).
Coremine identified 3594 and 2045 genes linked
to biological terms concerning “Cell Proliferation”
and “DNA damage and repair” processes, respectivelyFigure 1 Venn diagram showing the numbers of DEGs shared
by the three comparisons.(Additional files 6 and 7). Intersections among these two
lists and the three lists of DEGs are shown in Additional
files 6 and 7.
Microarray data validation
The differential expression of nine transcripts (Table 1)
identified by microarray analysis was validated by RT-
qPCR and consistently confirmed for all the thirteen vali-
dations (six for M1775RvsWT, four for A1789TvsWT,
three for MutvsWT) (Figure 3).
The differential expression of GPR56, MRE11A, PML
and NFKB1 proteins was also confirmed by Western
Blot analysis (Figure 4).
Discussion
Aim of this study was the analysis of the effects on
human cell transcriptome of two missense variants
located in the second BRCT domain of BRCA1, M1775R
and A1789T. Specifically, the gene expression profiles of
HeLa cells transfected with one or the other variant
were compared with that of HeLa cells transfected with
BRCA1 wild-type. Three different statistical contrasts
were performed: M1775RvsWT, A1789TvsWT and
MutvsWT, considering the two variants as a single mu-
tation in the latter case.
Pathway analysis retrieved many pathways involved in
cancer onset and progression as well as linked to specific
tumors, as shown in Figure 5.
The information retrieved by pathway analysis was
completed by ontological and data-mining analyses,
which highlighted three functional categories: cell cycle
regulation, apoptosis and DNA damage response and
Figure 3 Microarray and RT-qPCR log2-Fold changes for the nine validated genes. All the log2-Fold changes are statistically significant
(p-value< 0.05).
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and apoptosis deregulation leads to aberrant cell prolif-
eration, while an impaired DNA damage response and re-
pair is known to cause genomic instability. All these
processes are closely connected, as apoptosis, constituting
a defense from anomalous proliferation, is linked to cell
cycle block and is activated in response to DNA damage.Aberrant cell proliferation
Cancer cells proliferate abnormally. In these cells, the
mechanisms ensuring correct cell division, which involve
cell cycle arrest at checkpoints, are impaired and there is
overexpression of mitogenic factors, such as cell cycle
positive regulators. Moreover, in cancer cells apoptosis is
often downregulated [25-27].
Figure 4 Western Blot analysis of the differential expression of
GPR56, MRE11A, PML and NFKB1 proteins.
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expressed genes is strictly linked to cell proliferation.
The DEGs linked to cell proliferation were involved
in three main phenomena: cell cycle arrest impairment,
cell proliferation enhancement and apoptosis blocking
(Table 2).Figure 5 Diagram showing the top fifteen most impacted
pathways for each contrast. The blue bar is proportional to the
number of DEGs mapped in each pathway.Cell cycle arrest impairment
CDKN1A, downregulated by M1775R, is a main effector
of cell cycle arrest in response to DNA damage and a
promoter of apoptosis [28]. Its expression is usually acti-
vated by BRCA1 [2].
Cell cycle can be also arrested by the cooperation of
CDKN1A with CEBPA that was in turn downregulated
by M1775R [29].
CDKN1A expression is normally activated also by
SMAD3, a known transcription factor that acts as an ef-
fector of the TGF-beta pathway [30], downregulated in
all the three comparisons. The overexpression of
SMAD3 in a breast cancer cell line has been shown to
cause cell cycle arrest [31], while in SMAD3−/− mam-
mary epithelial cells, both TGF-beta-induced growth in-
hibition and apoptosis are lost [32].SMAD3 also contributes to the 3-indole-induced G1
arrest in cancer cells [33] and its inhibition depends on
CCND1-CDK4 (cyclin-dependent kinase 4) action in
breast cancer cells overexpressing CCND1 [34], which
appeared upregulated by A1789T. The loss or reduction
of BRCA1 expression, moreover, significantly reduces
the TGF-beta induced activation of SMAD3 in breast
cancer cells [35].
Four other genes linked to cell cycle control appeared
downregulated, two, PML and RUVBL1, by M1775R and
Table 2 Genes linked to aberrant cell proliferation
Biological Process Gene
Symbol




CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) M1775RvsWT −0.3066647
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha M1775RvsWTMutvsWT −0.3728651
−0.3190284
SMAD3 SMAD family member 3 A1789TvsWTM1775RvsWTMutvsWT −0.2675322
−0.4286813
−0.3196246
CCND1 cyclin D1 A1789TvsWT 0.3622112
PML promyelocytic leukemia M1775RvsWT −0.3045759
RUVBL1 RuvB-like 1 (E. coli) M1775RvsWT −0.3028029
TXNIP thioredoxin interacting protein A1789TvsWT −0.3985633










DUSP1 dual specificity phosphatase 1 A1789TvsWTM1775RvsWTMutvsWT 0.3844494
0.7606655
0.5060076
DUSP2 dual specificity phosphatase 2 MutvsWT 0.5408689
EDN1 endothelin 1 M1775RvsWTMutvsWT 0.4442705
0.3212824
SKP1 S-phase kinase-associated protein 1 A1789TvsWT 0.3353208
ZWILCH Zwilch, kinetochore associated, homolog
(Drosophila)
A1789TvsWT 0.2508541





NFKB 1 nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
M1775RvsWT −0.2522979






PLEKHF1 pleckstrin homology domain containing, family F
(with FYVE domain) member 1
MutvsWT −0.2374774
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phosphoprotein localized in nuclear bodies involved in
recognition and/or processing of DNA breaks and able
to arrest cell cycle in G1 by recruiting TP53 and
MRE11A [36]; RUVBL1 encodes a highly conserved
ATP-dependent DNA helicase that plays a role in apop-
tosis and DNA repair [37]; TXNIP acts as a tumor sup-
pressor, as its transfection induces cell-cycle arrest
in G0/G1 and is downregulated in human tumors [38]
and RASSF1 is a tumor suppressor that blocks cell cycle
progression by inhibiting CCND1 accumulation. It isepigenetically inactivated in many tumors, including
breast cancer [39,40].
Cell proliferation enhancement
The transcription factor FOS, upregulated in all the
three comparisons, is a well known protooncogene that
positively regulates cell cycle progression [41] and is
induced in human breast cancer cell cultures [25].
DUSP1, upregulated in all the three comparisons, and
DUSP2, upregulated in MutvsWT, belong to a subfamily
of tyrosine phosphatases that regulate the activity of
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are key effectors for cell growth control and survival in
physiological and pathological conditions, including can-
cer and DUSPs have been therefore proposed as poten-
tial targets for anticancer drugs [42]. DUSP1 inhibits
apoptosis in human mammary epithelial and breast car-
cinoma cells [43] and its expression is upregulated in
many breast cancers [44]. The overexpression of DUSP2
in ovarian cancers has been correlated with poor out-
come [45].
EDN1, upregulated by M1775R and in MutvsWT,
is a vasoconstrictor that has also co-mitogenic activity,
potentiating the growth factor effects. Altered EDN1 sig-
nalling is involved in carcinogenesis by modulating cell
survival and promoting invasiveness [46].
SKP1, upregulated by A1789T, is a component of the
SCF complex that mediates the ubiquitination of cell
cycle proteins promoting cell cycle progression [47].
ZWILCH, upregulated by A1789T, is an essential com-
ponent of the mitotic checkpoint that prevents cells
from exiting mitosis prematurely [48].
GPR56, downregulated in all the three contrasts, is a
G protein-coupled receptor involved in adhesion pro-
cesses that participates in cytoskeletal signaling, cellular
adhesion and tumor invasion. It is downregulated in
melanoma cell lines, while its overexpression suppresses
tumor growth and metastasis [49].
Apoptosis blocking
NFKB1, downregulated by M1775R, is a pleiotropic tran-




DNA damage response and
repair downregulation
EEF1E1 eukaryotic translation elongation
factor 1 epsilon 1
SMC1A structural maintenance of chromos
PPP1CC protein phosphatase 1, catalytic sub
gamma isozyme
AHNAK AHNAK nucleoprotein
SOD2 superoxide dismutase 2, mitochond
DNA damage response
and repair upregulation
MRE11A MRE11 meiotic recombination 11
homolog A (S. cerevisiae)





fold containing 2Blike inflammation, immunity, differentiation, cell growth,
tumorigenesis and apoptosis. Whether NFKB activation
contributes or not to cancer is controversial [50], as it
regulates the expression of both antiapoptotic [51] and
proapoptotic genes [52,53].
Interestingly, TNFRSF10B, that was in turn downregu-
lated by M1775R, is one of the proapoptotic genes upre-
gulated by NFKB [53]. TNFRSF10B is one of the two
apoptosis-activating receptors binding TNFSF10 (tumor
necrosis factor (ligand) superfamily, member 10) [54]
that, together with FADD (Fas(TNFRSF6)-Associated via
Death Domain) forms a complex that leads to apoptosis
through caspases activation [55].
DYRK2, downregulated by M1775R, is a protein kinase
that regulates TP53 in inducing apoptosis in response to
DNA damage [56] and PLEKHF1, downregulated in
MutvsWT, is a recently discovered lysosome-associated
protein that activates apoptosis [57] by interacting with
the TP53 transactivation domain [58].
Genomic instability
An improper reaction to genotoxic stress causes gen-
omic instability, leading to tumorigenesis. Deficiencies in
DNA damage signaling and repair pathways are thus
fundamental to the etiology of cancer [59].
Among the DEGs involved in genotoxic stress response,
some were downregulated causing an increase in genomic
instability, others were upregulated (Table 3). Many
tumors, including BRCA1-deficient breast cancers, show
an overexpression of genes linked to DNA repair that cor-
relates with chemoresistance and poor prognosis [60,61].Contrast log2
(Fold Change)
A1789TvsWT −0.4309041
omes 1A A1789TvsWT MutvsWT −0.2754507−0.2640263
unit, A1789TvsWT −0.4286825
A1789TvsWT M1775RvsWT MutvsWT −0.3988113
−0.3103867
−0.3940570





ding A1789TvsWT MutvsWT 0.4070777
0.3417360
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proteins has been recently observed in tissue sections of
breast cancers carrying the M1775R mutation, suggesting
a new mechanism of tumorigenesis that involves an
enhance of homologous recombination [62].
DNA damage response and repair downregulation
EEF1E1, downregulated by A1789T, first discovered as
associated with a macromolecular tRNA synthetase
complex, is a key factor for ATM/ATR-mediated TP53
activation in response to DNA damage [63].
SMC1A, downregulated by A1789T and in MutvsWT,
encodes an evolutionarily conserved chromosomal pro-
tein, component of the cohesin complex [64]. SMC1A
associates with BRCA1 and is phosphorylated in response
to ionizing radiations in an ATM- and NBN-dependent
manner [65].
PPP1CC, downregulated by A1789T, is the catalytic
subunit of the gamma isoform of PP1 which is a compo-
nent of a signaling complex, PPP1R1A/PPP1R15A/PP1
that positively regulates apoptosis in response to various
stresses, including growth arrest and DNA damage [66].
AHNAK, downregulated in all the three contrasts,
encodes a protein typically repressed in human neuro-
blastoma cell lines and in other types of tumors [67]. It
firmly binds the LIG4-XRCC4 (ligase IV, DNA, ATP-
dependent and X-ray repair complementing defective
repair in Chinese hamster cells 4) complex on DNA
stimulating its double-stranded ligation activity [68].
SOD2, downregulated by M1775R and in MutvsWT, is
a member of the iron/manganese superoxide dismutase
family that acts as a free radical scavenger. It is a candi-
date tumor suppressor gene as the loss of heterozigosity
of its region on chromosome 6 has been found in about
40% of human malignant melanomas [69] and the dele-
tion of chromosome 6 long arm has been identified in
SV40 transformed human fibroblasts [70]. In addition,
SOD2 overexpression suppresses the tumorigenicity of
breast cancer cells [71].
DNA damage response and repair upregulation
MRE11A, upregulated by A1789T, encodes a component
of BASC (Brca1 Associated genome Surveillance Com-
plex), which specifically promotes non-homologous end-
joining [72,73]. Interestingly, the A1789T variant altered
the non-homologous end-joining activity in a functional
assay [11].
TERF1, upregulated in MutvsWT, is a telomere-
associated protein, member of the telomere nucleopro-
tein complex that interacts with various polypeptides,
like the MRN complex [74].
OBFC2A, upregulated by M1775R, and OBFC2B,
upregulated by A1789T and in MutvsWT, encode single-
stranded DNA-binding proteins essential for DNAreplication, recombination and damage detection and
repair. OBFC2B, in particular, as an early participant in
DNA damage response, is critical for genomic stability [75].Conclusions
As we first observed in yeast cells [11], also in human
cells the BRCA1 variants M1775R and A1789T affect the
expression of many genes critical for cell proliferation
and genome integrity maintenance. Our results repre-
sent the first molecular confirmation of the pathogenetic
role of M1775R. In fact, although more than an evidence
exists on the pathogenetic role of this BRCA1 variant,
the effect of this mutation on human cell transcriptome
has never been investigated before.
Concerning the A1789T variant, it has been studied
only by our group. On the basis of experiments in yeast,
we previously suggested for this mutation a causative
role in breast cancer onset and development similar to
that of M1775R. The present work gives further support
to this hypothesis.Additional files
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